Acrivon Therapeutics Takes Full Control of ACR-368 Diagnostic Development In-House
Summary
Acrivon Therapeutics is bringing the development and commercialization of its ACR-368 OncoSignature diagnostic test in-house, gaining full control over a critical component of its lead oncology program.
Key Events
-
Agreement Termination
Acrivon Therapeutics and Akoya Biosciences mutually terminated their OncoSignature Companion Diagnostic Agreement, effective February 25, 2026.
-
In-House CLIA Lab
The termination follows Acrivon's recent completion and certification of its own Clinical Laboratory Improvement Amendment (CLIA) certified laboratory.
-
Strategic Control
Acrivon gains full development and commercialization rights to its proprietary ACR-368 OncoSignature test, enhancing control over biomarker identification and diagnostic development.
-
Operational Efficiency
Bringing CLIA operations in-house is expected to improve capabilities and efficiencies, streamlining co-regulatory approvals and co-commercialization for current and future therapeutic agents.
Analysis
Acrivon Therapeutics has terminated its agreement with Akoya Biosciences, bringing the development and commercialization of its proprietary ACR-368 OncoSignature diagnostic test in-house. This strategic move, enabled by the company's newly certified CLIA laboratory, grants Acrivon full control over biomarker identification, companion diagnostic development, and regulatory processes for its lead oncology asset, ACR-368. This enhances operational efficiency and streamlines the path for potential co-regulatory approvals and co-commercialization, particularly important following recent positive Phase 2b clinical data for ACR-368.
At the time of this filing, ACRV was trading at $1.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.3M. The 52-week trading range was $1.05 to $5.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.